Work

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-146547

Authors: Guillermo Garcia-Manero, Harry P. Erba, Srinivasa R. Sanikommu, Jessica K. Altman, Hamid Sayar, Bart L. Scott, Abraham P. Fong, Shanhong Guan, Feng Jin, Alison J. Forgie, Jaume Pons, Sophia S. Randolph, Michael T. Byrne

Institutions: The University of Texas MD Anderson Cancer Center, Duke University, Levine Cancer Institute, Northwestern University, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Fred Hutch Cancer Center, ALX Oncology Inc. (United States), Vanderbilt University Medical Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3212540727

Cites:

Cited by: 17

Related to: 10